Article

This review focuses on the most recent data on biotherapeutic approaches, using
DNA, RNA, recombinant proteins, or cells as therapeutic tools or targets for the
treatment of neuromuscular diseases. Many of these novel technologies have now
reached the clinical stage and have or are about to move to the market. Others,
like genome editing are still in an early stage but hold great promise.
CI - Copyright (c) 2014 Elsevier Masson SAS. All rights reserved.

Langue : ANGLAIS